Evercore ISI Has Lowered Expectations for Hologic (NASDAQ:HOLX) Stock Price

Hologic (NASDAQ:HOLX - Free Report) had its price target reduced by Evercore ISI from $76.00 to $73.00 in a report released on Thursday,Benzinga reports. Evercore ISI currently has an in-line rating on the medical equipment provider's stock.

Several other research analysts have also recently issued reports on HOLX. UBS Group increased their target price on shares of Hologic from $84.00 to $90.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. Needham & Company LLC lowered shares of Hologic from a "buy" rating to a "hold" rating and set a $90.00 price objective on the stock. in a report on Monday, February 3rd. Raymond James upped their target price on Hologic from $93.00 to $95.00 and gave the stock an "outperform" rating in a report on Tuesday, November 5th. William Blair reiterated an "outperform" rating on shares of Hologic in a report on Monday, January 13th. Finally, Leerink Partners cut Hologic from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $80.00 to $75.00 in a research note on Thursday. Ten investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Hologic presently has an average rating of "Moderate Buy" and a consensus target price of $85.77.

Hologic Trading Up 1.0 %

HOLX stock traded up $0.66 during mid-day trading on Thursday, reaching $65.24. The company had a trading volume of 3,020,034 shares, compared to its average volume of 2,581,862. The firm has a 50 day moving average of $72.33 and a 200 day moving average of $77.76. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 3.03. Hologic has a 12 month low of $63.62 and a 12 month high of $84.67. The company has a market capitalization of $14.73 billion, a PE ratio of 20.58, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX - Get Free Report) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $1.03 EPS for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, equities analysts predict that Hologic will post 4.27 earnings per share for the current fiscal year.

Insider Transactions at Hologic

In other Hologic news, COO Essex D. Mitchell sold 24,856 shares of the business's stock in a transaction that occurred on Wednesday, December 4th. The stock was sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the transaction, the chief operating officer now directly owns 27,957 shares of the company's stock, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 1.88% of the company's stock.

Institutional Trading of Hologic

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. FMR LLC grew its holdings in shares of Hologic by 64.0% during the third quarter. FMR LLC now owns 5,572,545 shares of the medical equipment provider's stock worth $453,940,000 after buying an additional 2,174,093 shares in the last quarter. Nordea Investment Management AB boosted its position in Hologic by 32.7% during the fourth quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider's stock worth $159,911,000 after acquiring an additional 544,889 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Hologic during the 4th quarter valued at about $27,007,000. Swedbank AB raised its holdings in Hologic by 18.8% in the 3rd quarter. Swedbank AB now owns 1,937,002 shares of the medical equipment provider's stock valued at $157,788,000 after acquiring an additional 306,562 shares during the last quarter. Finally, JPMorgan Chase & Co. lifted its stake in Hologic by 21.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,358,945 shares of the medical equipment provider's stock worth $110,700,000 after purchasing an additional 238,222 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company's stock.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.